National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Last Modified: 6/30/2009     First Published: 8/25/2007  
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

Quick Links
Help Using the NCI Clinical Trials Search Form

Educational Materials About Clinical Trials

About NCI's Cancer Clinical Trials Registry

Dictionary of Cancer Terms

NCI Drug Dictionary
Phase III Randomized Study of Consolidation Therapy Comprising Bortezomib and Dexamethasone With Versus Without Lenalidomide in Patients With Symptomatic Multiple Myeloma Who Have Completed a Dexamethasone-Based Induction Regimen

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Published Results
Trial Contact Information
Related Information
Registry Information

Alternate Title

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActive18 and overNCIECOG-E1A05
E1A05, NCT00522392

Special Category: CTSU trial, NCI Web site featured trial

Objectives

Primary

  1. To compare the progression-free survival (PFS) of patients with previously treated symptomatic multiple myeloma treated with consolidation therapy comprising bortezomib and dexamethasone with vs without lenalidomide.

Secondary

  1. To determine the incremental ability of these regimens in attaining a complete response or a very good partial response (VGPR) in these patients.
  2. To compare the overall survival of patients treated with these regimens.
  3. To compare the toxicity of these regimens in these patients.
  4. To compare the quality of life of these patients.
  5. To examine the impact of differential treatment response, if observed, on quality of life of these patients.
  6. To obtain prospective data on multiple myeloma specific quality of life attributes.

Entry Criteria

Disease Characteristics:

  • Diagnosis of symptomatic multiple myeloma


  • Must meet the following criteria at one point in the course of the disease for the original diagnosis of myeloma:
    • Bone marrow plasmacytosis with > 10% plasma cells or sheets of plasma cells or biopsy proven plasmacytoma
    • Must have symptomatic disease that prompted the initiation of therapy (e.g., anemia, hypercalcemia, bone disease, or renal dysfunction)


  • Must have completed a minimum of 1 and a maximum of 6 courses of a dexamethasone-based regimen within the past 8 weeks, including any of the following:
    • Dexamethasone alone
    • Vincristine, doxorubicin, and dexamethasone
    • Thalidomide and dexamethasone
    • Lenalidomide and dexamethasone
    • Liposomal doxorubicin and dexamethasone
    • The combination of any of the above agents and dexamethasone
    • Cyclophosphamide, lenalidomide, and dexamethasone


  • Received a minimum cumulative dose of 160 mg of dexamethasone (no maximum dose specified)


  • Must have not experienced progressive disease on the dexamethasone-based regimen


  • Patients diagnosed with only smoldering myeloma or monoclonal gammopathy of undetermined significance are not eligible


Prior/Concurrent Therapy:

  • See Disease Characteristics
  • At least 14 days since prior palliative and/or localized radiotherapy
  • Prior bortezomib allowed
  • Concurrent bisphosphonates or growth factors (e.g., granulocyte and/or erythropoietic agents) for multiple myeloma allowed

Patient Characteristics:

  • ECOG performance status 0-2
  • Hemoglobin > 7 g/dL
  • Platelet count > 75,000/mm3
  • Absolute neutrophil count > 1,000/mm3 (without the use of growth factors to increase ANC)
  • Creatinine < 2.5 mg/dL
  • Direct bilirubin < 1.5 mg/dL
  • ALT and AST < 2.5 times upper limit of normal
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective double-method contraception for 4 weeks prior to, during, and for 4 weeks after completion of study therapy
  • No active uncontrolled seizure disorder
  • No seizure within the past 6 months
  • No concurrent uncontrolled illness that would limit compliance with the study, including any of the following:
    • Uncontrolled hypertension
    • Symptomatic congestive heart failure
    • Unstable angina
    • Uncontrolled cardiac arrhythmia
    • Uncontrolled psychiatric illness or social situation
    • History of Steven Johnson syndrome
  • No peripheral neuropathy ≥ grade 2
  • No active uncontrolled infection
  • Patients with a history of prior malignancy are eligible provided there is no active malignancy AND there is a low expectation of recurrence within 6 months
  • Must be willing and able to receive prophylaxis with aspirin (325 mg/day) or alternative prophylaxis with low molecular weight heparin or coumadin
    • Patients with prior DVT are eligible provided they remain on the anticoagulation regimen that was prescribed for treatment of the DVT throughout study therapy

Expected Enrollment

392

Outcomes

Primary Outcome(s)

Progression-free survival

Secondary Outcome(s)

Response rates (complete response and very good partial response)
Overall survival rates
Difference in rate of all grade 3 or higher toxicity
Difference in the mean change in the FACT-Ntx TOI score from study registration (prior to randomization) to 6 months post-consolidation treatment
Impact of the differential treatment survival on quality of life at clinically meaningful timepoints (i.e., prior to study randomization, at the beginning of course 5, at the end of course 8, and at 3, 6, 9, and 12 months after treatment)

Outline

Patients are stratified according to prior induction therapy with lenalidomide and dexamethasone (yes vs no) and whether or not they are in complete response after induction therapy at study registration (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive bortezomib IV on days 1, 4, 8, and 11, oral lenalidomide once a day on days 1-14, and oral dexamethasone once a day on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.


  • Arm II: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral dexamethasone once a day on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.


Quality of life is assessed periodically.

After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then every 12 months for 5 years.

Published Results

Fonseca R, Rajkumar SV: Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial. Clin Lymphoma Myeloma 8 (5): 315-7, 2008.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Eastern Cooperative Oncology Group

Rafael Fonseca, MD, Protocol chair
Ph: 480-301-6118
Email: fonseca.rafael@mayo.edu
S. Rajkumar, MD, Protocol chair
Ph: 507-284-8430
Email: rajks@mayo.edu

Trial Sites

U.S.A.
Alabama
  Mobile
 Providence Cancer Center at Providence Hospital
 Thaddeus Beeker
Ph: 251-633-1890
Alaska
  Anchorage
 Providence Cancer Center
 Clinical Trials Office - Providence Cancer Center
Ph: 907-261-3109
Arizona
  Scottsdale
 Mayo Clinic Scottsdale
 Clinical Trials Office - All Mayo Clinic Locations
Ph: 507-538-7623
California
  Fairfield
 North Bay Cancer Center
 Clinical Trials Office - North Bay Cancer Center
Ph: 707-429-6976
  Sacramento
 University of California Davis Cancer Center
 Clinical Trials Office - University of California Davis Cancer Center
Ph: 916-734-3089
  San Diego
 Kaiser Permanente Medical Office -Vandever Medical Office
 Han Koh
Ph: 619-528-2596
Delaware
  Lewes
 Tunnell Cancer Center at Beebe Medical Center
 Clinical Trials Office - Tunnell Cancer Center
Ph: 302-645-3171
  Newark
 CCOP - Christiana Care Health Services
 Clinical Trial Office - CCOP - Christiana Care Health Services
Ph: 302-733-6227
Florida
  Jacksonville
 Mayo Clinic - Jacksonville
 Clinical Trials Office - All Mayo Clinic Locations
Ph: 507-538-7623
Georgia
  Atlanta
 CCOP - Atlanta Regional
 Thomas Seay, MD, PhD
Ph: 404-851-2340
 Northside Hospital Cancer Center
 Clinical Trials Office - Northside Hospital Cancer Center
Ph: 404-303-3355
 Piedmont Hospital
 Thomas Seay, MD, PhD
Ph: 404-851-2340
 Saint Joseph's Hospital of Atlanta
 Clinical Trials Office - Saint Joseph's Hospital of Atlanta
Ph: 404-851-7115
  Austell
 WellStar Cobb Hospital
 Clinical Trials Office - WellStar Cobb Hospital
Ph: 770-793-5980
  Decatur
 Charles B. Eberhart Cancer Center at DeKalb Medical Center
 Thomas Seay, MD, PhD
Ph: 404-851-2340
  Lawrenceville
 Gwinnett Medical Center
 Thomas Seay, MD, PhD
Ph: 404-851-2340
  Marietta
 Kennestone Cancer Center at Wellstar Kennestone Hospital
 Clinical Trials Office - Kennestone Cancer Center
Ph: 770-793-5980
  Riverdale
 Southern Regional Medical Center
 Clinical Trials Office - Southern Regional Medical Center
Ph: 770-991-8611
  Rome
 Harbin Clinic Cancer Center - Medical Oncology
 Thomas Seay, MD, PhD
Ph: 404-851-2340
Illinois
  Alton
 Saint Anthony's Hospital at Saint Anthony's Health Center
 Bethany Sleckman, MD
Ph: 314-251-7057
  Canton
 Graham Hospital
 John Kugler, MD
Ph: 309-243-3605
  Carthage
 Memorial Hospital
 John Kugler, MD
Ph: 309-243-3605
  Eureka
 Eureka Community Hospital
 John Kugler, MD
Ph: 309-243-3605
  Galesburg
 Galesburg Clinic, PC
 John Kugler, MD
Ph: 309-243-3605
 Galesburg Cottage Hospital
 John Kugler, MD
Ph: 309-243-3605
 InterCommunity Cancer Center of Western Illinois
 John Kugler, MD
Ph: 309-243-3605
  Havana
 Mason District Hospital
 John Kugler, MD
Ph: 309-243-3605
  Hinsdale
 Hinsdale Hematology Oncology Associates
 Elyse Schneiderman, MD
Ph: 630-654-1790
  Hopedale
 Hopedale Medical Complex
 John Kugler, MD
Ph: 309-243-3605
  Macomb
 McDonough District Hospital
 John Kugler, MD
Ph: 309-243-3605
  Mt. Vernon
 Good Samaritan Regional Health Center
 Bethany Sleckman, MD
Ph: 314-251-7057
  Normal
 BroMenn Regional Medical Center
 John Kugler, MD
Ph: 309-243-3605
 Community Cancer Center
 John Kugler, MD
Ph: 309-243-3605
  Ottawa
 Community Hospital of Ottawa
 John Kugler, MD
Ph: 309-243-3605
 Oncology Hematology Associates of Central Illinois, PC - Ottawa
 John Kugler, MD
Ph: 309-243-3605
  Pekin
 Cancer Treatment Center at Pekin Hospital
 John Kugler, MD
Ph: 309-243-3605
  Peoria
 CCOP - Illinois Oncology Research Association
 John Kugler, MD
Ph: 309-243-3605
 Methodist Medical Center of Illinois
 Clinical Trials Office - Methodist Medical Center of Illinois
Ph: 309-243-3000
 Oncology Hematology Associates of Central Illinois, PC - Peoria
 John Kugler, MD
Ph: 309-243-3605
 Proctor Hospital
 John Kugler, MD
Ph: 309-243-3605
  Peru
 Illinois Valley Community Hospital
 John Kugler, MD
Ph: 309-243-3605
  Princeton
 Perry Memorial Hospital
 John Kugler, MD
Ph: 309-243-3605
  Rockford
 Swedish-American Regional Cancer Center
 Clinical Trials Office - Swedish-American Regional Cancer Center
Ph: 815-489-4413
  Spring Valley
 St. Margaret's Hospital
 John Kugler, MD
Ph: 309-243-3605
 Valley Cancer Center
 John Kugler, MD
Ph: 309-243-3605
  Springfield
 Regional Cancer Center at Memorial Medical Center
 Clinical Trials Office - Regional Cancer Center at Memorial Medical Center
Ph: 217-788-4233
Indiana
  Beech Grove
 St. Francis Hospital and Health Centers - Beech Grove Campus
 Howard Gross, MD
Ph: 937-832-1093
  Fort Wayne
 Fort Wayne Medical Oncology and Hematology
 Sreenivasa Nattam, MD
Ph: 260-484-8830
  Indianapolis
 Indiana University Melvin and Bren Simon Cancer Center
 Clinical Trials Office - Indiana University Cancer Center
Ph: 317-274-2552
 Veterans Affairs Medical Center - Indianapolis
 Rafat Abonour, MD
Ph: 317-274-0843
 William N. Wishard Memorial Hospital
 Rafat Abonour, MD
Ph: 317-274-0843
  Munster
 Community Hospital
 Erwin Robin, MD
Ph: 219-836-2860
  Richmond
 Reid Hospital & Health Care Services
 Howard Gross, MD
Ph: 937-832-1093
Iowa
  Ames
 McFarland Clinic, PC
 Clinical Trials Office - McFarland Clinic, PC
Ph: 515-239-2621
  Des Moines
 CCOP - Iowa Oncology Research Association
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
 John Stoddard Cancer Center at Iowa Lutheran Hospital
 Clinical Trials Office - John Stoddard Cancer Center at Iowa Lutheran Hospital
Ph: 515-241-8704
 John Stoddard Cancer Center at Iowa Methodist Medical Center
 Clinical Trials Office - John Stoddard Cancer Center at Iowa Methodist Medical Center
Ph: 515-241-6727
 Medical Oncology and Hematology Associates at John Stoddard Cancer Center
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
 Medical Oncology and Hematology Associates at Mercy Cancer Center
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
 Mercy Cancer Center at Mercy Medical Center - Des Moines
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
 Mercy Capitol Hospital
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
  Mason City
 Mercy Cancer Center at Mercy Medical Center - North Iowa
 Clinical Trials Office - Mercy Cancer Center at Mercy Medical Center - North Iowa
Ph: 641-422-6304
  Ottumwa
 McCreery Cancer Center at Ottumwa Regional
 Robert Behrens
Ph: 641-684-2946
  Waterloo
 Cedar Valley Medical Specialists, PC - West Ridgeway Avenue
 Boriana Kamenova
Ph: 319-833-5907
 Covenant Cancer Treatment Center
 Clinical Trials Office - Covenant Cancer Treatment Center
Ph: 319-272-2070
Kansas
  Wichita
 Wesley Medical Center
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
Maryland
  Elkton MD
 Union Hospital Cancer Program at Union Hospital
 Gregory Masters, MD
Ph: 302-366-1200
Michigan
  Adrian
 Hickman Cancer Center at Bixby Medical Center
 Clinical Trials Office - Hickman Cancer Center at Bixby Medical Center
Ph: 517-265-0116
  Kalamazoo
 Borgess Medical Center
 Raymond Lord, MD
Ph: 269-373-7458
 Bronson Methodist Hospital
 Raymond Lord, MD
Ph: 269-373-7458
 West Michigan Cancer Center
 Clinical Trials Office - West Michigan Cancer Center
Ph: 269-373-7458
  Lambertville
 Haematology-Oncology Associates of Ohio and Michigan, PC
 Paul Schaefer, MD
Ph: 419-479-5605
  Monroe
 Community Cancer Center of Monroe
 Paul Schaefer, MD
Ph: 419-479-5605
 Mercy Memorial Hospital - Monroe
 Paul Schaefer, MD
Ph: 419-479-5605
Minnesota
  Bemidji
 MeritCare Bemidji
 Preston Steen, MD
Ph: 701-234-2397
  Duluth
 CCOP - Duluth
 Daniel Nikcevich, MD, PhD
Ph: 218-786-3625
 Duluth Clinic Cancer Center - Duluth
 Clinical Trials Office - Duluth Clinic Cancer Center - Duluth
Ph: 218-786-3308
 Miller - Dwan Medical Center
 Daniel Nikcevich, MD, PhD
Ph: 218-786-3625
  Hutchinson
 Hutchinson Area Health Care
 Daniel Anderson
Ph: 320-234-5000
800-454-3903
  Maplewood
 HealthEast Cancer Care at St. John's Hospital
 Daniel Anderson
Ph: 651-232-7970
  Minneapolis
 Hennepin County Medical Center - Minneapolis
 Clinical Trials Office - Hennepin County Medical Center - Minneapolis
Ph: 612-873-5911
 Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
 Clinical Trials Office - Virginia Piper Cancer Institute
Ph: 612-863-5654
  Rochester
 Mayo Clinic Cancer Center
 Clinical Trials Office - All Mayo Clinic Locations
Ph: 507-538-7623
  St. Paul
 Regions Hospital Cancer Care Center
 Clinical Trials Office - Regions Hospital Cancer Care Center
Ph: 651-254-1517
Missouri
  Cape Girardeau
 Saint Francis Medical Center
 Bethany Sleckman, MD
Ph: 314-251-7057
 Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
 Bethany Sleckman, MD
Ph: 314-251-7057
  Columbia
 Ellis Fischel Cancer Center at University of Missouri - Columbia
 Clinical Trial Office - Ellis Fischel Cancer Center
Ph: 573-882-4894
  Saint Louis
 CCOP - St. Louis-Cape Girardeau
 Bethany Sleckman, MD
Ph: 314-251-7057
 David C. Pratt Cancer Center at St. John's Mercy
 Clinical Trials Office - David C. Pratt Cancer Center at St. John's Mercy
Ph: 314-251-6770
 Midwest Hematology Oncology Group, Incorporated
 Bethany Sleckman, MD
Ph: 314-251-7057
  Springfield
 CCOP - Cancer Research for the Ozarks
 Robert Carolla
Ph: 417-269-4520
 Hulston Cancer Center at Cox Medical Center South
 Robert Carolla
Ph: 417-269-5257
 St. John's Regional Health Center
 Robert Carolla
Ph: 417-820-2000
Montana
  Billings
 Billings Clinic - Downtown
 Clinical Trials Office - Billings Clinic - Downtown
Ph: 800-996-2663
 Email: research@billingsclinic.org
 CCOP - Montana Cancer Consortium
 Benjamin Marchello, MD
Ph: 406-238-6290
 Hematology-Oncology Centers of the Northern Rockies - Billings
 Benjamin Marchello, MD
Ph: 406-238-6290
 Northern Rockies Radiation Oncology Center
 Benjamin Marchello, MD
Ph: 406-238-6290
 St. Vincent Healthcare Cancer Care Services
 Benjamin Marchello, MD
Ph: 406-238-6290
  Butte
 St. James Healthcare Cancer Care
 Benjamin Marchello, MD
Ph: 406-238-6290
  Great Falls
 Benjamin Marchello, MD
Ph: 406-238-6290
 Great Falls Clinic - Main Facility
 Benjamin Marchello, MD
Ph: 406-238-6290
  Havre
 Northern Montana Hospital
 Benjamin Marchello, MD
Ph: 406-238-6290
  Kalispell
 Glacier Oncology, PLLC
 Benjamin Marchello, MD
Ph: 406-238-6290
 Kalispell Medical Oncology at KRMC
 Benjamin Marchello, MD
Ph: 406-238-6290
 Kalispell Regional Medical Center
 Benjamin Marchello, MD
Ph: 406-238-6290
  Missoula
 Community Medical Center
 Benjamin Marchello, MD
Ph: 406-238-6290
 Guardian Oncology and Center for Wellness
 Benjamin Marchello, MD
Ph: 406-238-6290
 Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
 Clinical Trials Office - Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Ph: 406-329-7029
 Montana Cancer Specialists at Montana Cancer Center
 Clinical Trials Office - Montana Cancer Specialists at Montana Cancer Center
Ph: 406-238-6962
Nebraska
  Kearney
 Good Samaritan Cancer Center at Good Samaritan Hospital
 Clinical Trials Office - Good Samaritan Cancer Center at Good Samaritan Hospital
Ph: 308-865-7963
  Omaha
 Alegant Health Cancer Center at Bergan Mercy Medical Center
 Clinical Trials Office - Alegant Health Cancer Center at Bergen Mercy Medical Center
Ph: 402-398-6060
 CCOP - Missouri Valley Cancer Consortium
 Gamini Soori, MD, FACP, FRCP, MBA
Ph: 402-393-3110
 Creighton University Medical Center
 Clinical Trials Office - Creighton University Medical Center
Ph: 402-280-4100
 Immanuel Medical Center
 Gamini Soori, MD, FACP, FRCP, MBA
Ph: 402-393-3110
Nevada
  Las Vegas
 CCOP - Nevada Cancer Research Foundation
 John Ellerton, MD, CM
Ph: 702-384-0013
 University Medical Center of Southern Nevada
 John Ellerton, MD, CM
Ph: 702-384-0013
New Jersey
  Brick
 Ocean Medical Center at Meridian Health
 Clinical Trials Office - Ocean Medical Center at Meridian Health
Ph: 732-206-8384
  Marlton
 Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
 Clinical Trials Office - Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
Ph: 888-847-8823
  Voorhees
 Cancer Institute of New Jersey at Cooper - Voorhees
 Clinical Trials Office - Cancer Institute of New Jersey at Cooper University Hospital - Voorhees
Ph: 856-325-6757
 Fox Chase Virtua Health Cancer Program at Virtua West Jersey
 Michael Entmacher, MD
Ph: 609-702-1900
New Mexico
  Albuquerque
 Lovelace Medical Center - Downtown
 Edward Libby
Ph: 505-727-8000
 Presbyterian Cancer Treatment Center at Presbyterian Kaseman Hospital
 Edward Libby
Ph: 505-291-2462
 University of New Mexico Cancer Center
 Clinical Trials Office - University of New Mexico Cancer Center
Ph: 505-272-6972
New York
  Bronx
 Our Lady of Mercy Medical Center Comprehensive Cancer Center
 Peter Wiernik, MD
Ph: 718-304-7200
  Brooklyn
 SUNY Downstate Medical Center
 William Solomon, MD
Ph: 718-270-2785
  Cooperstown
 Bassett Healthcare Regional Cancer Program at Mary Imogene Bassett Hospital
 Eric Bravin, MD
Ph: 607-547-3336
  Glens Falls
 Adirondack Cancer Care - Glens Falls
 Mark Hoffman, MD
Ph: 518-761-0000
  Middletown
 Tucker Center for Cancer Care at Orange Regional Medical Center
 Clinical Trials Office - Tucker Center for Cancer Care at Orange Regional Medical Center
Ph: 845-342-7609
  Staten Island
 Nalitt Cancer Institute at Staten Island University Hospital
 Marcel Odaimi
Ph: 718-226-6400
North Carolina
  Asheboro
 Randolph Hospital
 Clinical Trails Office - Randolph Hospital
Ph: 336-832-0821
  Charlotte
 Presbyterian Cancer Center at Presbyterian Hospital
 Clinical Trials Office - Presbyterian Cancer Center at Presbyterian Hospital
Ph: 704-384-5369
  Greensboro
 Moses Cone Regional Cancer Center at Wesley Long Community Hospital
 Clinical Trials Office - Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Ph: 336-621-8374
  Kinston
 Kinston Medical Specialists
 Peter Watson, MD
Ph: 252-559-2200ext.201
  Reidsville
 Annie Penn Cancer Center
 Clinical Trials Office - Annie Penn Cancer Center
Ph: 336-621-8374
North Dakota
  Fargo
 CCOP - MeritCare Hospital
 Preston Steen, MD
Ph: 701-234-2397
 MeritCare Broadway
 Preston Steen, MD
Ph: 701-234-2397
Ohio
  Bellefontaine
 Mary Rutan Hospital
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Bowling Green
 Wood County Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
  Canton
 Aultman Cancer Center at Aultman Hospital
 Clinical Trials Office - Aultman Cancer Center at Aultman Hospital
Ph: 330-363-6891
 Mercy Cancer Center at Mercy Medical Center
 Mitchell Haut, MD
Ph: 330-453-9993
  Chillicothe
 Adena Regional Medical Center
 Clinical Trials Office - Adena Regional Medical Center
Ph: 877-779-7585
  Cleveland
 MetroHealth Cancer Care Center at MetroHealth Medical Center
 Bruce Averbook, MD, FACS
Ph: 216-778-4795
  Columbus
 CCOP - Columbus
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
 Doctors Hospital at Ohio Health
 Clinical Trials Office - Doctors Hospital at Ohio Health
Ph: 614-566-3275
 Grant Medical Center Cancer Care
 Clinical Trials Office - Grant Medical Center Cancer Care
Ph: 614-566-4475
 Mount Carmel Health - West Hospital
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
 Riverside Methodist Hospital Cancer Care
 Clinical Trials Office - Riverside Methodist Hospital Cancer Care
Ph: 614-566-4475
  Dayton
 CCOP - Dayton
 Howard Gross, MD
Ph: 937-832-1093
 David L. Rike Cancer Center at Miami Valley Hospital
 Clinical Trials Office - David L. Rike Cancer Center at Miami Valley Hospital
Ph: 937-208-2079
 Good Samaritan Hospital
 Howard Gross, MD
Ph: 937-832-1093
 Grandview Hospital
 Howard Gross, MD
Ph: 937-832-1093
 Samaritan North Cancer Care Center
 Howard Gross, MD
Ph: 937-832-1093
 Veterans Affairs Medical Center - Dayton
 Howard Gross, MD
Ph: 937-832-1093
  Delaware
 Grady Memorial Hospital
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Elyria
 Hematology Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
  Findlay
 Blanchard Valley Medical Associates
 Howard Gross, MD
Ph: 937-832-1093
  Franklin
 Middletown Regional Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Greenville
 Wayne Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Kettering
 Charles F. Kettering Memorial Hospital
 Clinical Trials Office - Charles F. Kettering Memorial Hospital
Ph: 937-298-3399 ext. 57556
  Lancaster
 Fairfield Medical Center
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Lima
 Lima Memorial Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 St. Rita's Medical Center
 Clinical Trials Office - St. Rita's Medical Center
Ph: 419-226-9617
  Marietta
 Strecker Cancer Center at Marietta Memorial Hospital
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Maumee
 Northwest Ohio Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
 Paul Schaefer, MD
Ph: 419-479-5605
 St. Luke's Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
  Newark
 Licking Memorial Cancer Care Program at Licking Memorial Hospital
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Oregon
 St. Charles Mercy Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Clinic - Oregon
 Paul Schaefer, MD
Ph: 419-479-5605
  Sandusky
 North Coast Cancer Care, Incorporated
 Paul Schaefer, MD
Ph: 419-479-5605
  Springfield
 Community Hospital of Springfield and Clark County
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
 Mercy Medical Center
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Sylvania
 Flower Hospital Cancer Center
 Clinical Trials Office - Flower Hospital Cancer Center
Ph: 419-824-1842
  Tiffin
 Mercy Hospital of Tiffin
 Paul Schaefer, MD
Ph: 419-479-5605
  Toledo
 CCOP - Toledo Community Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 Medical University of Ohio Cancer Center
 Clinical Trials Office - Medical University of Ohio Cancer Center
Ph: 419-383-6583
 St. Anne Mercy Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 St. Vincent Mercy Medical Center
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Clinic, Incorporated - Main Clinic
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Hospital
 Clinical Trials Office - Toledo Hospital
Ph: 419-824-1842
  Troy
 UVMC Cancer Care Center at Upper Valley Medical Center
 Clinical Trials Office - UVMC Cancer Care Center at Upper Valley Medical Center
Ph: 937-440-4842
  Wauseon
 Fulton County Health Center
 Clinical Trials Office - Fulton County Health Center
Ph: 419-330-2708
  Westerville
 Mount Carmel St. Ann's Cancer Center
 J. Philip Kuebler, MD, PhD
Ph: 614-442-3130
  Wilmington
 Clinton Memorial Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Xenia
 Ruth G. McMillan Cancer Center at Greene Memorial Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Zanesville
 Genesis - Good Samaritan Hospital
 Clinical Trials Office - Genesis - Good Samaritan Hospital
Ph: 740-454-5232
Oregon
  Gresham
 Legacy Mount Hood Medical Center
 Clinical Trials Office - Legacy Mount Hood Medical Center
Ph: 503-413-2150
  Milwaukie
 Providence Milwaukie Hospital
 Keith Lanier, MD
Ph: 503-299-6500
  Portland
 Adventist Medical Center
 Keith Lanier, MD
Ph: 503-299-6500
 CCOP - Columbia River Oncology Program
 Keith Lanier, MD
Ph: 503-299-6500
 Legacy Emanuel Hospital and Health Center and Children's Hospital
 Clinical Trials Office - Legacy Emanuel Hospital and Health Center and Children's Hospital
Ph: 503-413-8199
 Legacy Good Samaritan Hospital & Comprehensive Cancer Center
 Clinical Trials Office - Legacy Good Samaritan Hospital & Comprehensive Cancer Center
Ph: 503-413-1742
 Providence Cancer Center at Providence Portland Medical Center
 Clinical Trials Office - Providence Cancer Center at Providence Portland Medical Center
Ph: 503-215-6412
 Providence St. Vincent Medical Center
 Clinical Trials Office - Providence St. Vincent Medical Center
Ph: 503-215-6412
  Tualatin
 Legacy Meridian Park Hospital
 Clinical Trials Office - Legacy Meridian Park Hospital
Ph: 503-413-1742
Pennsylvania
  Abington
 Rosenfeld Cancer Center at Abington Memorial Hospital
 Clinical Trials Office - Rosenfeld Cancer Center at Abington Memorial Hospital
Ph: 215-481-2402
  Bryn Mawr
 Bryn Mawr Hospital
 Clinical Trials Office - Bryn Mawr Hospital
Ph: 610-645-2680
  Doylestown
 Doylestown Hospital Cancer Center
 Mitchell Alden, DO
Ph: 215-345-8444
  Hershey
 Penn State Cancer Institute at Milton S. Hershey Medical Center
 Clinical Trials Office - Penn State Cancer Institute at Milton S. Hershey Medical Center
Ph: 717-531-3779
 Email: CTO@hmc.psu.edu
  Lancaster
 Lancaster General Hospital
 Randall Oyer
Ph: 717-544-5511
  Lemoyne
 Central Pennsylvania Hematology and Medical Oncology Associates, PC
 John Conroy, DO, FACP, FACOI
Ph: 717-737-5767
  Lewistown
 Lewistown Hospital
 Giampaolo Talamo
Ph: 717-242-7143
  Paoli
 Cancer Center of Paoli Memorial Hospital
 Clinical Trials Office - Cancer Center of Paoli Memorial Hospital
Ph: 610-648-1637
  Pottstown
 Pottstown Memorial Regional Cancer Center
 Wei Song, MD, PhD
Ph: 610-327-7555
  Reading
 McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
 Clinical Trials Office - McGlinn Family Regional Cancer Center
Ph: 610-988-9323
  Sellersville
 Grand View Hospital
 Anthony Magdalinski, III
Ph: 215-453-4000
  State College
 Mount Nittany Medical Center
 Giampaolo Talamo
Ph: 814-231-7000
  Wynnewood
 CCOP - Main Line Health
 Paul Gilman, MD
Ph: 610-645-2000
 Lankenau Cancer Center at Lankenau Hospital
 Paul Gilman, MD
Ph: 610-645-2000
South Carolina
  Florence
 McLeod Regional Medical Center
 Clinical Trials Office - McLeod Regional Medical Center
Ph: 843-679-7256
South Dakota
  Rapid City
 Rapid City Regional Hospital
 Richard Tenglin
Ph: 605-719-2360
Tennessee
  Memphis
 University of Tennessee Cancer Institute - Memphis
 Clinical Trials Office - University of Tennessee Cancer Institute
Ph: 901-448-3303
Virginia
  Danville
 Danville Regional Medical Center
 Clinical Trials Office - Danville Regional Medical Center
Ph: 434-799-3753
  Fredericksburg
 Fredericksburg Oncology, Incorporated
 Paul Schaefer, MD
Ph: 419-479-5605
  Richmond
 Virginia Commonwealth University Massey Cancer Center
 Clinical Trials Office -Virginia Commonwealth University Massey Cancer Center
Ph: 804-628-1939
Washington
  Vancouver
 Southwest Washington Medical Center Cancer Center
 Keith Lanier, MD
Ph: 503-299-6500
West Virginia
  Charleston
 West Virginia University Health Sciences Center - Charleston
 Steven Jubelirer, MD
Ph: 304-388-8380
Wisconsin
  Chippewa Falls
 Marshfield Clinic - Chippewa Center
 Matthias Weiss, MD
Ph: 715-358-1266
  Eau Claire
 Center for Cancer Treatment & Prevention at Sacred Heart Hospital
 Matthias Weiss, MD
Ph: 715-358-1266
 Marshfield Clinic Cancer Care at Regional Cancer Center
 Matthias Weiss, MD
Ph: 715-358-1266
  La Crosse
 Franciscan Skemp Healthcare - La Crosse Campus
 Haleem Rasool
Ph: 608-782-9760
 Gundersen Lutheran Center for Cancer and Blood
 Clinical Trials Office - Gundersen Lutheran Cancer Center
Ph: 608-775-2385
 Email: cancerctr@gundluth.org
  Madison
 Dean Medical Center - Madison
 Contact Person
Ph: 608-252-8000
800-844-6015
 University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
 Clinical Trials Office - University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Ph: 608-262-5223
  Marshfield
 Marshfield Clinic - Marshfield Center
 Clinical Trials Office - Marshfield Clinic - Marshfield Center
Ph: 800-782-1581 ext. 94457
 Saint Joseph's Hospital
 Matthias Weiss, MD
Ph: 715-358-1266
  Minocqua
 Marshfield Clinic - Lakeland Center
 Matthias Weiss, MD
Ph: 715-358-1266
  Oconomowoc
 Regional Cancer Center at Oconomowoc Memorial Hospital
 Clinical Trials Office - Regional Cancer Center at Oconomowoc Memorial Hospital
Ph: 262-928-7878
  Rhinelander
 Ministry Medical Group at Saint Mary's Hospital
 Matthias Weiss, MD
Ph: 715-358-1266
  Rice Lake
 Marshfield Clinic - Indianhead Center
 Matthias Weiss, MD
Ph: 715-358-1266
  Stevens Point
 Saint Michael's Hospital Cancer Center
 Matthias Weiss, MD
Ph: 715-358-1266
  Waukesha
 Waukesha Memorial Hospital Regional Cancer Center
 Clinical Trials Office - Waukesha Memorial Hospital Regional Cancer Center
Ph: 262-928-7632
  Wausau
 Marshfield Clinic - Wausau Center
 Matthias Weiss, MD
Ph: 715-358-1266
  Weston
 Marshfield Clinic - Weston Center
 Matthias Weiss, MD
Ph: 715-358-1266
  Wisconsin Rapids
 Marshfield Clinic - Wisconsin Rapids Center
 Matthias Weiss, MD
Ph: 715-358-1266
Republic of South Africa
  Pretoria
 Pretoria Academic Hospital
 Lydia Dreosti
Ph: 27-12-354-1000

Related Information

Featured trial article

Registry Information
Official Title Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®)- Lenalidomide (Revlimid®) -Dexamethasone (VRD) versus Bortezomib (Velcade®) - Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen
Trial Start Date 2007-08-21
Trial Completion Date 2009-08-25 (estimated)
Registered in ClinicalTrials.gov NCT00522392
Date Submitted to PDQ 2007-08-07
Information Last Verified 2009-06-30
NCI Grant/Contract Number CA21115

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov